stoxline Quote Chart Rank Option Currency Glossary
Agenus Inc. (AGEN)
14.56  0.99 (7.3%)    06-21 16:00
Open: 13.57
High: 14.68
Volume: 580,129
Pre. Close: 13.57
Low: 13.33
Market Cap: 306(M)
Technical analysis
2024-06-21 4:50:27 PM
Short term     
Mid term     
Targets 6-month :  18.69 1-year :  22.99
Resists First :  16 Second :  19.69
Pivot price 15.9
Supports First :  10.05 Second :  8.36
MAs MA(5) :  14.17 MA(20) :  15.5
MA(100) :  12.39 MA(250) :  17.96
MACD MACD :  0.5 Signal :  1
%K %D K(14,3) :  18.4 D(3) :  16.3
RSI RSI(14): 51.2
52-week High :  38.59 Low :  4.78
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ AGEN ] has closed above bottom band by 25.9%. Bollinger Bands are 4.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 14.7 - 14.78 14.78 - 14.84
Low: 13.17 - 13.24 13.24 - 13.31
Close: 14.42 - 14.56 14.56 - 14.68
Company Description

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Headline News

Mon, 17 Jun 2024
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors - Business Wire

Sun, 16 Jun 2024
Agenus Inc. (NASDAQ:AGEN) Sees Large Drop in Short Interest - MarketBeat

Sun, 16 Jun 2024
Agenus Inc. (NASDAQ:AGEN) Short Interest Update - Defense World

Tue, 21 May 2024
There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise - Simply Wall St

Thu, 09 May 2024
Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results - Simply Wall St

Tue, 07 May 2024
Agenus Inc (AGEN) Q1 2024 Earnings: Misses Revenue and EPS Estimates Amid Strategic Developments - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 21 (M)
Shares Float 18 (M)
Held by Insiders 1.2 (%)
Held by Institutions 50.2 (%)
Shares Short 3,140 (K)
Shares Short P.Month 2,590 (K)
Stock Financials
EPS 11.6
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -9.61
Profit Margin -148.4 %
Operating Margin -117.5 %
Return on Assets (ttm) -25.9 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 22.2 %
Gross Profit (p.s.) 0
Sales Per Share 7.68
EBITDA (p.s.) -5.9
Qtrly Earnings Growth 0 %
Operating Cash Flow -204 (M)
Levered Free Cash Flow -69 (M)
Stock Valuations
PE Ratio 1.25
PEG Ratio 0
Price to Book value -1.52
Price to Sales 1.89
Price to Cash Flow -1.5
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android